Novartis is developing fevipiprant, a CRTh2 antagonist, for the oral treatment of allergic conditions. Phase III clinical development is underway for the
... Read more
Before I researched why the post-Vietnam generation of Veterans were not joining Veteran Service Organizations (VSO), I asked myself, “Why wouldn’t veterans want to be around other veterans?”
... Read more